Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-four brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and eighteen have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $298.09.

Several research firms recently issued reports on ALNY. Raymond James increased their target price on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an "outperform" rating in a report on Friday, November 1st. Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Canaccord Genuity Group increased their price objective on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a report on Friday, November 1st. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a "neutral" rating in a report on Monday, August 26th.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded up $0.24 during midday trading on Wednesday, hitting $254.15. 453,455 shares of the company's stock traded hands, compared to its average volume of 862,560. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The stock has a market capitalization of $32.78 billion, a price-to-earnings ratio of -96.91 and a beta of 0.32. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The firm has a fifty day moving average of $268.29 and a 200 day moving average of $247.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The company's quarterly revenue was down 33.3% compared to the same quarter last year. During the same period last year, the company earned $1.15 earnings per share. On average, analysts forecast that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current year.

Insider Activity

In other news, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. This represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 8,370 shares of company stock worth $2,100,703. Corporate insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ALNY. Cetera Advisors LLC purchased a new stake in Alnylam Pharmaceuticals during the first quarter valued at approximately $238,000. Sequoia Financial Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 13.7% in the second quarter. Sequoia Financial Advisors LLC now owns 3,308 shares of the biopharmaceutical company's stock worth $804,000 after buying an additional 398 shares during the last quarter. Wedmont Private Capital purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $321,000. Diversified Trust Co purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $1,210,000. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Alnylam Pharmaceuticals by 40.2% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 4,131 shares of the biopharmaceutical company's stock worth $1,004,000 after buying an additional 1,184 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.